Treatment of metastatic melanoma: an overview.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Oncology

• Publication date

  2009-05-12

• Fields of study

  Medicine

• Identifiers
  PMID 19544689PMCID PMC2737459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

  2011cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2009cited by this paper
• Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

  2008cited by this paper
• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

  2008cited by this paper
• Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

  2008cited by this paper
• Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

  2008cited by this paper
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008cited by this paper
• Temozolomide for the treatment of metastatic melanoma: a systematic review.

  2007cited by this paper
• Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

  2007cited by this paper
• Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

  2007cited by this paper
• Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma

  2007cited by this paper
• Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma

  2007cited by this paper
• Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.

  2006cited by this paper
• Treatments for metastatic melanoma: synthesis of evidence from randomized trials.

  2006cited by this paper
• Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.

  2006cited by this paper
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  2006cited by this paper
• Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma

  2006cited by this paper
• High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial

  2005cited by this paper
• Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.

  2005cited by this paper
• Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

  2004cited by this paper
• Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma

  2002cited by this paper
• Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

  2002cited by this paper
• Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.

  2002cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Paclitaxel and tamoxifen

  2000cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

  2000cited by this paper
• Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.

  2000cited by this paper
• Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

  1999cited by this paper
• Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

  1999cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

  1998cited by this paper
• Prognostic factors for survival of patients treated systemically for disseminated melanoma.

  1998cited by this paper
• Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

  1998cited by this paper
• Surgical treatment of metastatic melanoma.

  1998cited by this paper
• Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.

  1996cited by this paper
• Prognostic factors in 1,521 melanoma patients with distant metastases.

  1995cited by this paper
• Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up

  1995cited by this paper
• Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

  1994cited by this paper
• Fotemustine in the treatment of brain primary tumors and metastases.

  1994cited by this paper
• The role of surgery in the treatment of nonregionally recurrent melanoma.

  1993cited by this paper
• Taxol in malignant melanoma.

  1993cited by this paper
• Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.

  1993cited by this paper
• A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

  1989cited by this paper
• Phase II trial of carboplatin in advanced malignant melanoma.

  1987cited by this paper
• WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

  1987cited by this paper
• Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.

  1986cited by this paper
• Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)

  1984cited by this paper
• Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.

  1984cited by this paper
• Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.

  1984cited by this paper

• A Case of Metastatic Melanoma Refractory to Immunotherapy: Is Cytotoxic Chemotherapy Still an Effective Option?

  2026cites this paper
• Assessing the Data Quality Dimensions of Surgical Oncology Cohorts in the All of Us Research Program.

  2025cites this paper
• Functionalized Cerium Oxide Nanoparticles Enhance Penetration into Melanoma Spheroids In Vivo through Angiogenesis

  2025cites this paper
• A Case of Retrorectal Melanoma Presenting With Bleeding Per Rectum

  2025cites this paper
• The application of 3D cell culture for melanoma in vitro models.

  2025cites this paper
• Bioactivity-guided characterisation of iberin from Cakile edentula (Bigelow) Hook. inducing apoptosis in human melanoma cells.

  2025cites this paper
• Lipid Nanoparticles and Skin: Discoveries and Advances

  2025cites this paper
• Ketamine and dodecyl maltoside synergy as a potential topical therapeutic approach for melanoma

  2025cites this paper
• Trends of all-cause, melanoma-specific, and cardiovascular mortality in melanoma patients from 2005 to 2020.

  2025cites this paper
• 3D bioprinting of cancer models: A game-changer in drug discovery and development.

  2025cites this paper
• Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis

  2025cites this paper
• Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases

  2025cites this paper
• Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises.

  2025cites this paper
• Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening

  2025cites this paper
• Surgery in patients with metastatic melanoma treated with immune checkpoint inhibitors

  2025cites this paper
• New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms.

  2025cites this paper
• Vaccines in Dermatology—Present and Future: A Review

  2025cites this paper
• Prevention of skin cancer

  2025cites this paper
• Nitric Oxide-Releasing Topical Treatments for Cutaneous Melanoma.

  2024cites this paper
• CRISPR-inhibition screen for lncRNAs linked to melanoma growth and metastasis

  2024cites this paper
• Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials

  2024cites this paper
• Pan-cancer analysis combined with experimental validation revealed that KTN1 is an immunological and prognostic biomarker

  2024cites this paper
• Exploring a specialized programmed-cell death patterns to predict the prognosis and sensitivity of immunotherapy in cutaneous melanoma via machine learning

  2024cites this paper
• From rest to repair: Safeguarding genomic integrity in quiescent cells.

  2024cites this paper
• Patient and Tumor Factors on Overall Survival in Spindle Cell Melanoma

  2024cites this paper
• Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR

  2024cites this paper
• Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors

  2024cites this paper
• Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy

  2024cites this paper
• One-dimensional copper oxide nanorods with potential anticancer effects against melanoma cells

  2024cites this paper
• Tellurium nanoparticles and Fucoidan-loaded dissolvable microneedles for combined photothermal therapy and anti-angiogenesis in melanoma treatment.

  2024cites this paper
• Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study

  2024cites this paper
• Synthesis of 3-formyl-eudistomin U with anti-proliferation, anti-migration and apoptosis-promoting activities on melanoma cells

  2023cites this paper
• Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy.

  2023cites this paper
• Synthesis, characterization, and development of alpha-pinene nanoemulsion as an apoptotic inducer with cytotoxicity activity on human melanoma and breast cancer

  2023cites this paper
• A Yeast Cell Wall Derived Hybrid Hydrogel with Photothermal and Immune Combined Modality Therapy for Enhanced Anti-Melanoma Efficacy

  2023cites this paper
• The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition

  2023cites this paper
• D2LFS2Net: Multi-class skin lesion diagnosis using deep learning and variance-controlled Marine Predator optimisation: An application for precision medicine

  2023cites this paper
• Morusinol extracted from Morus alba induces cell cycle arrest and apoptosis via inhibition of DNA damage response in melanoma by CHK1 degradation through the ubiquitin-proteasome pathway.

  2023cites this paper
• Nanomedicine: A pragmatic approach for tackling melanoma skin cancer

  2023cites this paper
• Treatment of Melanoma Metastasis: Surgical, Chemotherapy, and Innovation

  2023influential citation
• A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma.

  2023cites this paper
• Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy

  2023cites this paper
• Combined ultrasound and photoacoustic C-mode imaging system for skin lesion assessment

  2023cites this paper
• The effects of patchouli alcohol and combination with cisplatin on proliferation, apoptosis and migration in B16F10 melanoma cells

  2023cites this paper
• Neoadjuvant treatment for stage III and IV cutaneous melanoma.

  2023cites this paper
• Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007–2017 database

  2023cites this paper
• Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?

  2023cites this paper
• CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells

  2023cites this paper
• Current Patterns of Treatment and Outcomes in Advanced Melanoma at a Single Institution.

  2023cites this paper
• Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity

  2023cites this paper
• Treatment and outcome trends and predictors of overall survival of rectal melanoma: Analysis of the National Cancer Database.

  2023cites this paper
• Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment.

  2023cites this paper
• Long noncoding RNA MAFG-AS1 enhances proliferation, invasion, and epithelial–mesenchymal transition of melanoma cells through promoting KIT expression by competitively binding to miR-331-3p

  2023cites this paper
• Primary malignant melanoma, an atypical presentation in the cervical spine: a case report

  2023cites this paper
• Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor

  2023cites this paper
• Methoxylated Cinnamic Esters with Antiproliferative and Antimetastatic Effects on Human Lung Adenocarcinoma Cells

  2023cites this paper
• Ovalbumin and Poly(i:c) Encapsulated Dendritic Cell‐Targeted Nanoparticles for Immune Activation in the Small Intestinal Lymphatic System

  2022cites this paper
• Did new treatments contribute to a decrease in melanoma deaths?

  2022cites this paper
• Self-made transparent optoacoustic detector for measurement of skin lesion thickness in vivo

  2022cites this paper
• Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma

  2022cites this paper
• Synthesis and anti-melanoma effect of 3-O-prenyl glycyrrhetinic acid against B16F10 cells via induction of endoplasmic reticulum stress-mediated autophagy through ERK/AKT signaling pathway

  2022cites this paper
• Immunotherapy-Induced Auto-Splenectomy in a Patient of Malignant Melanoma

  2022cites this paper
• Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells

  2022cites this paper
• Biosurfactants as Anticancer Agents: Glycolipids Affect Skin Cells in a Differential Manner Dependent on Chemical Structure

  2022cites this paper
• Synthesis of cinnamic acid ester derivatives with antiproliferative and antimetastatic activities on murine melanoma cells.

  2022cites this paper
• Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

  2022cites this paper
• The new horizon of biomarker in melanoma patients

  2022cites this paper
• Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics

  2022cites this paper
• A Rare Presentation of a Solitary Melanoma Bone Metastasis

  2022cites this paper
• The immune environment of bone sarcomas

  2022cites this paper
• Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma

  2022cites this paper
• Bilberry Anthocyanins (Vaccinium myrtillus L.) Induced Apoptosis of B16-F10 Cells and Diminished the Effect of Dacarbazine

  2022cites this paper
• Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells

  2022cites this paper
• In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II

  2022cites this paper
• Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review

  2022cites this paper
• Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance

  2022cites this paper
• CEBPB is associated with active tumor immune environment and favorable prognosis of metastatic skin cutaneous melanoma

  2022cites this paper
• Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma

  2022cites this paper
• Methyl Gallate Suppresses Tumor Development by Increasing Activation of Caspase3 and Disrupting Tumor Angiogenesis in Melanoma

  2022cites this paper
• Thyroid Dysfunction in Non‐Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta‐Analysis

  2022cites this paper
• Microenvironment in Oral Potentially Malignant Disorders: Multi-Dimensional Characteristics and Mechanisms of Carcinogenesis

  2022cites this paper
• Creation of noncontact device for use in brain metastasis margin identification in ex vivo mouse brain

  2022cites this paper
• Selective anti-cancer activity against melanoma cells using 3-O-acetyl-β-boswellic acid-loaded 3D-Printed scaffold

  2022cites this paper
• Perineural Spread of Melanoma: Lessons Learned the Hard Way

  2022cites this paper
• Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials

  2022cites this paper
• Hollow MnO2 for tumor-targeting chemo-photodynamic therapy for melanoma

  2022cites this paper
• OTT_A_286350 1291..1304

  2021cites this paper
• Immunotherapy for Melanoma.

  2021cites this paper
• Metastatic melanomas: Treatment overview

  2021cites this paper
• Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape

  2021cites this paper
• Phenotypic Switching of B16F10 Melanoma Cells as a Stress Adaptation Response to Fe3O4/Salicylic Acid Nanoparticle Therapy

  2021cites this paper
• Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers

  2021cites this paper
• Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies

  2021cites this paper
• 1510-Article Text-7165-1-11-20210518.docx

  2021cites this paper
• Magnetic nanoparticles in theranostics of malignant melanoma

  2021cites this paper
• PTGS2, CD133, CDK5 knockout comparison by CRISPR CAS-9 system in UV-Induced and Metastatic Melanoma

  2021cites this paper
• CD133 Promotes Resistance to Trametinib in Melanoma Stem Cells by Activating an AKT / BCL-2 Survival Pathway

  2021cites this paper
• Freckles, Lentigos, Melanocytic Nevi, and Melanoma

  2021cites this paper
• DEVELOPMENT AND BIOLOGICAL EVALUATION OF THERANOSTIC NANOSYSTEMS BASED ON NANOCRYSTALLINE CELLULOSE AND LIGNIN NANOPARTICLES

  2021cites this paper
• Advances in the discovery and development of melanoma drug therapies

  2021influential citation